GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alpha Teknova Inc (NAS:TKNO) » Definitions » Net-Net Working Capital

Alpha Teknova (Alpha Teknova) Net-Net Working Capital : $-0.17 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Teknova Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Alpha Teknova's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $-0.17.

The industry rank for Alpha Teknova's Net-Net Working Capital or its related term are showing as below:

TKNO's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.02
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Alpha Teknova Net-Net Working Capital Historical Data

The historical data trend for Alpha Teknova's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Teknova Net-Net Working Capital Chart

Alpha Teknova Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
-1.57 -1.37 2.51 -0.03 -0.03

Alpha Teknova Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.47 0.07 -0.03 -0.17

Competitive Comparison of Alpha Teknova's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Teknova's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Alpha Teknova's Price-to-Net-Net-Working-Capital falls into.



Alpha Teknova Net-Net Working Capital Calculation

Alpha Teknova's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(28.484+0.75 * 3.948+0.5 * 11.594-38.551
-0-0)/40.7938
=-0.03

Alpha Teknova's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(21.596+0.75 * 4.56+0.5 * 11.207-37.439
-0-0)/40.8234
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Alpha Teknova  (NAS:TKNO) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Alpha Teknova Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Alpha Teknova's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Teknova (Alpha Teknova) Business Description

Traded in Other Exchanges
N/A
Address
2451 Bert Drive, Hollister, CA, USA, 95023
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification.
Executives
Ken Gelhaus officer: Chief Commercial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Stephen Gunstream director, officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
J Matthew Mackowski director 343 SANSOME ST, SUITE 1215, SANSASAN FRANCISCO CA 94104
Matthew Lowell officer: Chief Financial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Damon Terrill officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
Thp Iv Affiliates Fund, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Lisa Hood officer: Chief People Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Irene Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Ted Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Iv, L.p. 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO MA 94108
Paul David Grossman director 1600 FARADAY AVENUE, CARLSBAD CA 92008
Brett Robertson director C/O INVUITY, INC., 444 DE HARO STREET, SAN FRANCOSCO CA 94107
Alexander C. Herzick director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Management Company, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108